Aug 2026· Current Hematologic Malignancy Reports· Vol 21· 0 citations· 122 references
Medicine
TL;DR
It is argued that PROs should be incorporated as a primary or co-primary endpoint in most modern clinical trials, rather than as a point of interest in exploratory analyses, to better align clinical trial data with patient-centered treatment tolerability.
Multiple myeloma (MM) remains characterized by recurrent relapse and cumulative treatment burden despite major therapeutic advances. This study compared conventional stepwise regimens with CAR-T cell therapy in terms of QoL, toxicity, cost, and ethical considerations within a model-based comparative framework. This com...
Guluzar Gulnur Itez, A. Sunguroğlu· Therapeutic Advances in Hema...· 0 citations
The ALPINE trial was a randomized, open-label study comparing the efficacy and safety of zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL). Using patient-reported outcome (PRO) data from the ALPINE trial, the current stud...
Timothy Victor, Gisoo Barnes, M. Shadman et al.· Blood Advances· 0 citations
Combination therapies are widely used in oncology due to their potential to improve therapeutic efficacy and overcome drug resistance. However, these potential advantages must be weighed against added toxicity, treatment burden, and costs. In this commentary, we examine some recent examples of divergent opinions by the...
F. de Jong, L. Douma, P. Baas et al.· Journal of the National Canc...· 0 citations
Multiple myeloma is a plasma cell malignancy associated with heterogeneous clinical outcomes. The majority of patients are diagnosed during their seventh decade and often present with age-related comorbidities and organ dysfunction. Myeloma therapeutic landscape is rapidly evolving with the introduction of immune-based...
Thomas George, R. Szalat· Cancer Journal· 0 citations
Pediatric advanced-stage Hodgkin lymphoma (HL) is highly curable, yet survivors treated with historical regimens face substantial late morbidity and excess mortality. Immunotherapy-based frontline therapies improve disease control, but late toxicities remain unknown. We developed a simulation model to project lifetime...
Jenn Rogers, Zachary J. Ward, Angela M. Feraco et al.· Journal of the National Canc...· 0 citations
Mantle cell lymphoma has multiple treatment options, yet the disease is difficult to cure. Relapses are common, treatments can cause severe side-effects, and current recommendations are still largely based on age rather than biology. Although suitability for intensive treatment was previously the decisive parameter, in...
Ingrid Glimelius, A. Nikkarinen, L. Meriranta et al.· The Lancet Haematology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.